Allotey Joel, Ruparel Vinita, McCallum Anna, Somal Karendeep, Simpson Louise, Gupta Gaurav, Lip Gerald, Sharma Ravi, Masannat Yazan
Department of Oncology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.
Department of Oncology, Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK.
Eur J Surg Oncol. 2025 Jan;51(1):108781. doi: 10.1016/j.ejso.2024.108781. Epub 2024 Oct 22.
Residual microcalcifications on mammograms after neoadjuvant chemotherapy (NACT) pose a challenge in surgical decision-making. This single-centre retrospective review of all patients who had NACT for breast cancer over five years, evaluated the relationship between pathological complete response and residual microcalcifications, controlling for tumour size, nodal stage, grade, and receptor status, as well as the impact of residual microcalcifications on recurrence and survival. There was no significant association between pathological complete response (pCR) and residual microcalcifications (p = 0.763). We computed hazard ratios (HR) for Time to recurrence (TTR) and overall survival (OS) which were both not significant, with HR = 2.599, [0.290, 23.264], p = 0.393 and HR = 1.362 [0.123, 15.062], p = 0.801 respectively. The predictive and prognostic significance of residual microcalcifications remains to be proven. The surgical excision of these lesions should be considered based on individual patient risk.
新辅助化疗（NACT）后乳腺钼靶片上的残余微钙化在手术决策中构成挑战。这项对五年内所有接受NACT治疗乳腺癌患者的单中心回顾性研究，评估了病理完全缓解与残余微钙化之间的关系，同时控制肿瘤大小、淋巴结分期、分级和受体状态，以及残余微钙化对复发和生存的影响。病理完全缓解（pCR）与残余微钙化之间无显著关联（p = 0.763）。我们计算了复发时间（TTR）和总生存期（OS）的风险比（HR），两者均无统计学意义，HR分别为2.599，[0.290, 23.264]，p = 0.393和HR = 1.362 [0.123, 15.062]，p = 0.801。残余微钙化的预测和预后意义仍有待证实。应根据个体患者风险考虑对这些病变进行手术切除。
